Takeda Pharmaceutical Company Ltd

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

Biopharma layoffs continue into 4Q 2024, affecting companies like Thermo Fisher, Charles River, Pfizer, Evonik, Johnson & Johnson, Bayer, Bristol Myers Squibb, AGC Biologics, and others. These layoffs are part of restructuring initiatives, site closures, and focus shifts in strategic core growth areas.

The FDA is reviewing Unicycive Therapeutics' oxylanthanum carbonate (OLC) for hyperphosphataemia in CKD dialysis patients, aiming to improve on current phosphate binder therapy. OLC requires fewer and smaller pills, potentially enhancing patient adherence. A survey highlighted the need for lower pill burden and better compliance. The global hyperphosphataemia market is $2.5 billion, with 75% of patients failing to meet serum phosphorus targets. Unicycive filed OLC under the 505(b)(2) pathway, requiring only three clinical trials.

89% of U.S. cancer centers faced chemotherapy drug shortages, including etoposide, crucial for extensive-stage small-cell lung cancer (ES-SCLC). In Canada, etoposide shortages from 2018-2020 led to a 'natural experiment' evaluating alternative treatments, revealing increased hospitalizations and shorter progression-free survival. The study suggested clinical practice guidelines for drug shortages and future research on their socioeconomic impacts. Meanwhile, a Japanese study on durvalumab plus carboplatin and etoposide for ES-SCLC patients with poor performance status showed promising tolerability and efficacy.

Biosimilars, nearly identical to original biologics, are revolutionizing the pharma industry by offering significant cost savings, with U.S. healthcare projected to save billions. Despite regulatory hurdles and a need for greater education among patients and providers, the biosimilar market is rapidly expanding globally, driven by patent expirations and supportive policies.

XOMA Royalty reports Q3 2024 financials: $7.2M income, FDA approval for Zevra’s MIPLYFFA™ (arimoclomol), $15M royalty monetization with Twist Bioscience, $9.9M cash receipts in Q3, $42.3M YTD.

The 'T-Cell Lymphoma Pipeline Insight Analysis Report' highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing treatments such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, drives innovation, aiming for better patient outcomes. The pipeline focuses on immune-modulating drugs, monoclonal antibodies, and targeted therapies, with Phase II trials dominating.

The T-Cell Lymphoma Pipeline Insight Analysis Report highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing therapies such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, accelerates novel treatment development, aiming to improve patient outcomes in this aggressive cancer.

AC Immune reports Q3 2024 financials: CHF 157.9M cash, JNJ-2056 Fast Track designation, CHF 24.6M milestone payment, and Phase 2 VacSYn trial on track for PD.